BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,521.18% | 4,318.01% | 4,999.86% | -44.76% | 237.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,521.18% | 4,318.01% | 4,999.86% | -44.76% | 237.08% |
| Cost of Revenue | 289.01% | 997.49% | 510.87% | 341.30% | 248.49% |
| Gross Profit | 3,746.00% | 5,248.50% | 6,709.68% | -45.85% | 231.12% |
| SG&A Expenses | 66.79% | 99.98% | 116.98% | 61.63% | 99.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.38% | 35.39% | 39.60% | 6.30% | 27.36% |
| Operating Income | 41.97% | 27.13% | 22.69% | -2,873.23% | -25.29% |
| Income Before Tax | 26.85% | -13.53% | -140.47% | -369.05% | -56.31% |
| Income Tax Expenses | -110.41% | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.21% | -12.59% | -143.25% | -369.05% | -56.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.24% | -0.90% | -11.16% | 131.57% | 7.29% |
| Net Income | 27.24% | -12.78% | -147.64% | -375.41% | -57.63% |
| EBIT | 41.97% | 27.13% | 22.69% | -2,873.23% | -25.29% |
| EBITDA | 42.27% | 27.28% | 22.75% | -2,020.17% | -25.64% |
| EPS Basic | 28.78% | -10.81% | -143.82% | -346.73% | -45.16% |
| Normalized Basic EPS | 31.36% | 17.78% | 10.45% | -959.38% | -26.71% |
| EPS Diluted | 28.78% | -10.81% | -143.82% | -346.73% | -45.16% |
| Normalized Diluted EPS | 31.36% | 17.78% | 10.45% | -959.38% | -26.71% |
| Average Basic Shares Outstanding | 2.17% | 1.77% | 1.56% | 6.40% | 8.58% |
| Average Diluted Shares Outstanding | 2.17% | 1.77% | 1.56% | 6.40% | 8.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |